{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011311","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.112660+00:00","generated_at":"2026-05-17T13:59:05.161918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dogwood Therapeutics Q2 net loss $3.8M; Halneuron Phase 2b interim data on track for Q4 2025","bullets":["Enrolled 52 patients in Halneuron Phase 2b CINP trial; low discontinuation rate of 5.8% due to adverse events.","R&D expenses $2.5M (up from $0.3M) driven by clinical trial costs; G&A $1.3M (up from $0.7M).","Net loss $3.8M ($1.99 per share) vs $1.0M ($1.15) in Q2 2024; no revenue reported.","Cash $13.4M expected to fund operations through Q1 2026; Halneuron fast-tracked by FDA.","IMC-1 (fibromyalgia) ready for Phase 3; IMC-2 (Long-COVID) paused due to government funding uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011311","json":"https://secwatch.observer/filing/0001558370-25-011311.json","markdown":"https://secwatch.observer/filing/0001558370-25-011311.md","text":"https://secwatch.observer/filing/0001558370-25-011311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025011311/0001558370-25-011311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025011311/dwtx-20250813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:59:05.161918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}